Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Role of mTOR inhibitor in cholangiocarcinoma cell progression

Penpak Moolthiya1, Rutaiwan Tohtong1, Siriporn Keeratichamroen2

  • 1Department of Biochemistry, Faculty of Science, Mahidol University, Rajathevi, Bangkok 10400, Thailand.

Oncology Letters
|February 15, 2014
PubMed

Insights

RAD001 (everolimus), an mTOR inhibitor, shows promise for treating cholangiocarcinoma (CCA). It reduced cancer cell invasion and migration at low doses and killed cancer cells at high doses, offering new therapeutic strategies for this lethal biliary tract cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cholangiocarcinoma (CCA) is a deadly biliary tract cancer.
  • Existing chemotherapy options for CCA are largely ineffective.
  • New therapeutic targets and drugs are urgently needed for CCA treatment.

Purpose of the Study:

  • To investigate the potential of RAD001 (everolimus), a mammalian target of rapamycin (mTOR) inhibitor, as a treatment for cholangiocarcinoma.
  • To evaluate the cytotoxic and anti-metastatic effects of RAD001 on CCA cells.

Main Methods:

  • Utilized the RMCCA-1 cholangiocarcinoma cell line.
  • Administered RAD001 at varying concentrations.
  • Assessed cell invasion, migration, actin cytoskeleton, and apoptosis.

Main Results:

  • Low concentrations of RAD001 reduced *in vitro* invasion and migration of RMCCA-1 cells.
  • RAD001 altered the actin cytoskeleton and reduced filopodia formation.
  • High concentrations of RAD001 induced cytotoxicity, inhibited proliferation, and promoted apoptotic cell death.

Conclusions:

  • RAD001 demonstrates significant anti-metastatic and cytotoxic effects in a CCA cell line.
  • mTOR inhibition by RAD001 offers a potential therapeutic strategy for cholangiocarcinoma.
  • RAD001 may serve as a promising agent for developing novel CCA treatments.
Keywords:
RAD001cholangiocarcinomamTOR inhibitor

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K